Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir (original) (raw)
- Original Article
- Published: 15 June 2000
- David Brust1,
- Julie Farnsworth1,2,
- Cyrus Amir1,2,3,
- Mohiuddin M Taher1,
- Chad Hershey1 &
- …
- Jeffrey Feden1
Cancer Gene Therapy volume 7, pages 879–884 (2000)Cite this article
- 267 Accesses
- 34 Citations
- Metrics details
Abstract
Adenovirus expressing herpes simplex virus-thymidine kinase (HSV-TK) sensitizes internal rat glioma cells to radiation in combination with acyclovir (ACV). However, relatively high concentrations of ACV (>10 μM) are required to obtain significant radiosensitization. Serum levels rarely reach more than the lower micromolar range, preventing the full use of this genetic approach to radiosensitize cells in vivo. To better use the lower concentrations of ACV available in sera, we constructed an adenovirus expressing a mutant HSV-TK (HSV-TK(75)) isolated for its ∼20 times greater sensitivity to ACV than wild-type (wt) HSV-TK. We demonstrate that rat RT2 glioma cells infected with adenovirus AdCMV-TK(75) and exposed to either ACV or ganciclovir become more sensitive to lower concentrations (1–3 μM) of the drugs compared with cells infected with AdCMV-TK(wt), which expresses wt HSV-TK. Most importantly, the RT2 cells become more sensitive to low doses (2–4 Gy) of 60Co radiation than cells infected with an adenovirus expressing wt HSV-TK. This sensitization is accompanied by an increased rate of apoptosis. In summary, we show that infection of rat glioma cells with an adenovirus expressing a mutant HSV-TK sensitizes the cells to low doses of radiation after exposure to ACV at lower concentrations than those required for wt HSV-TK. This finding suggests that this mutant adenovirus may improve the in vivo efficacy of HSV-TK-based cancer gene therapy approaches.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond, 23298, Virginia
Kristoffer Valerie, David Brust, Julie Farnsworth, Cyrus Amir, Mohiuddin M Taher, Chad Hershey & Jeffrey Feden - Massey Cancer Center, Medical College of Virginia, Virginia Commonwealth University, Richmond, 23298, Virginia
Kristoffer Valerie, Julie Farnsworth & Cyrus Amir - Department of Biostatistics, Medical College of Virginia, Virginia Commonwealth University, Richmond, 23298, Virginia
Cyrus Amir
Authors
- Kristoffer Valerie
You can also search for this author inPubMed Google Scholar - David Brust
You can also search for this author inPubMed Google Scholar - Julie Farnsworth
You can also search for this author inPubMed Google Scholar - Cyrus Amir
You can also search for this author inPubMed Google Scholar - Mohiuddin M Taher
You can also search for this author inPubMed Google Scholar - Chad Hershey
You can also search for this author inPubMed Google Scholar - Jeffrey Feden
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toKristoffer Valerie.
Rights and permissions
About this article
Cite this article
Valerie, K., Brust, D., Farnsworth, J. et al. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir.Cancer Gene Ther 7, 879–884 (2000). https://doi.org/10.1038/sj.cgt.7700185
- Received: 06 August 1999
- Accepted: 30 November 1999
- Published: 15 June 2000
- Issue Date: 01 June 2000
- DOI: https://doi.org/10.1038/sj.cgt.7700185